GenomOncology said its GO Pathology Workbench decision support system is being used by Personalis as part of its clinical cancer reporting process, with the goal of accelerating the return of clinical cancer reports to ordering physicians, and organizing the report’s findings more intuitively to aid their decision making.
GO Pathology Workbench is designed to provide a customized workflow for laboratories to analyze sequencing data efficiently and manage relevant molecular testing results from NGS and other test modes, including FISH, karyotyping, RT-PCR, IHC, and Array.
“Our goal is to enable precision oncology by connecting disparate tools and databases, allowing data to flow end to end to aid case workflow. The Pathology Workbench provides reporting that is comprehensive and actionable, thus supporting decision making by oncologists,” GenomOncologhy Founder and CEO Manuel J. Glynias said yesterday in a statement.
Personalis is a provider of advanced genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. Personalis uses the software to perform quality control analysis, evaluate genetic alterations, and manage any required confirmations, amendments or addendums as required.
“With GO's Pathology Workbench integrated with the Personalis ACE Platform, turnaround time for clinical reports can be reduced by several days, returning potentially actionable results to physicians faster,” added Erin Ayash, a genomic counselor at Personalis.
GO Pathology Workbench is the flagship product of the GO portfolio, a full suite of tools that according to GenomOncology are designed to enable real-time decision support at the point-of-care to accelerate precision oncology and improve patient outcomes. The software is installed behind an institution's firewall, and configured to the specific needs of each lab.
GO Clinical Workbench uses GenomOncology’s Knowledge Management System (GO KMS), designed to provide direct access to gene and variant-level information derived from the precision cancer medicine knowledge resource My Cancer Genome—as well as allow Personalis to curate additional knowledge as it is discovered in the lab.
GO KMS is based on research by Vanderbilt University's My Cancer Genome team led by Mia Levy, M.D., Ph.D. GO KMS is designed to match a patient's biomarkers to therapies, prognoses and clinical trials, ensuring that Personalis’ clinical cancer reporting highlights relevant therapies and clinical trials by partner institutions.